These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 22938785

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cell-based medicinal chemistry optimization of high throughput screening hits for orally active antimalarials. Part 2: hits from SoftFocus kinase and other libraries.
    Younis Y, Street LJ, Waterson D, Witty MJ, Chibale K.
    J Med Chem; 2013 Oct 24; 56(20):7750-4. PubMed ID: 23927599
    [Abstract] [Full Text] [Related]

  • 12. Virtual compound screening in drug discovery.
    Stumpfe D, Ripphausen P, Bajorath J.
    Future Med Chem; 2012 Apr 24; 4(5):593-602. PubMed ID: 22458679
    [Abstract] [Full Text] [Related]

  • 13. High-throughput screening and structure-based approaches to hit discovery: is there a clear winner?
    Jhoti H, Rees S, Solari R.
    Expert Opin Drug Discov; 2013 Dec 24; 8(12):1449-53. PubMed ID: 24206191
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In silico pharmacology for a multidisciplinary drug discovery process.
    Ortega SS, Cara LC, Salvador MK.
    Drug Metabol Drug Interact; 2012 Dec 24; 27(4):199-207. PubMed ID: 23152402
    [Abstract] [Full Text] [Related]

  • 18. Hit discovery and hit-to-lead approaches.
    Keseru GM, Makara GM.
    Drug Discov Today; 2006 Aug 24; 11(15-16):741-8. PubMed ID: 16846802
    [Abstract] [Full Text] [Related]

  • 19. Case study: technology initiative led to advanced lead optimization screening processes at Bristol-Myers Squibb, 2004-2009.
    Zhang L, Cvijic ME, Lippy J, Myslik J, Brenner SL, Binnie A, Houston JG.
    Drug Discov Today; 2012 Jul 24; 17(13-14):733-40. PubMed ID: 22425710
    [Abstract] [Full Text] [Related]

  • 20. Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles.
    Sanders JM, Beshore DC, Culberson JC, Fells JI, Imbriglio JE, Gunaydin H, Haidle AM, Labroli M, Mattioni BE, Sciammetta N, Shipe WD, Sheridan RP, Suen LM, Verras A, Walji A, Joshi EM, Bueters T.
    J Med Chem; 2017 Aug 24; 60(16):6771-6780. PubMed ID: 28418656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.